HPWA
UBX

Hall Private Wealth Advisors’s Unity Biotechnology UBX Stock Holding History

Hall Private Wealth Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,850
Closed -$56K – 53
2021
Q3 		$56K Hold
1,850
– – 0.04% 51
2021
Q2 		$86K Buy
+1,850
New +$89.1K 0.06% 51

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Hall Private Wealth Advisors's UBX Position: Q4 2021 in Review

Hall Private Wealth Advisors sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 1,850 shares — an estimated $56K sold.

Hall Private Wealth Advisors first reported a position in UBX in Q2 2021 and held it in 2 quarters. The position peaked at $86K in Q2 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • Hall Private Wealth Advisors reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Hall Private Wealth Advisors sold 1,850 Unity Biotechnology shares in Q4 2021, an estimated $56K.
  • Hall Private Wealth Advisors first reported a position in Unity Biotechnology in Q2 2021 and held it in 2 quarters.
  • Hall Private Wealth Advisors's Unity Biotechnology position peaked at $86K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Hall Private Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.